Meta AnalysisID 6664
不同抗抑郁药与中成药治疗成人重度抑郁障碍急性期的疗效和可接受性比较：系统评价与网状Meta分析
CRD42020195728
Network meta-analysis was used to compare and rank the efficacy and safety of different Chinese patent drugs and antidepressants in the treatment of depression to observe which treatment is better.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6664
- Evidence Id
- 15222
- Core Evidence Id
- 15222
- Source Meta Analysis Id
- 6647
- Herb2 Meta Analysis Id
- HBMA006647
- Crd Id
- CRD42020195728
- Title
- Comparative efficacy and acceptability of different antidepressant drugs and Chinese patent medicine for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
- Review Question
- Network meta-analysis was used to compare and rank the efficacy and safety of different Chinese patent drugs and antidepressants in the treatment of depression to observe which treatment is better.
- Study Type Included
- The language and publication form are not limited and the case control study for Chinese patent medicine or antidepressant treatment of depression.The subjects of the study were patients with depression, and specific diagnostic criteria were required to be reported.By reading literature, we can calculate the OR value and 95% CI of the relationship between different proprietary Chinese medicine and antidepressant and depression, OR the estimated value and standard error of logistic regression coefficient.
- Condition Being Studied
- Major deprssive disorder (MDD) is a debilitating mental disorder characterized by low mood and mood disorders.High prevalence rate, high recurrence rate and high disability rate are difficult problems in the prevention and treatment of MDD, and the lifetime prevalence rate of patients with MDD is up to 13.2%, which seriously affects the learning, life and social functions of patients .At present, there are about 350 million people suffering from depression in the world, and the incidence of depression is increasing year by year with the increase of work and life pressure. WHO predicts that it will become the second disease in the world in 2020, which will not only affect the patients themselves, but also bring unimaginable burdens to their families and even the society. And depression can cause many somatic diseases that affect normal life.
- Participant
- The language and publication form are not limited and the case control study for Chinese patent medicine or antidepressant treatment of depression.The subjects of the study were patients with depression, and specific diagnostic criteria were required to be reported.By reading literature, we can calculate the OR value and 95% CI of the relationship between different proprietary Chinese medicine and antidepressant and depression, OR the estimated value and standard error of logistic regression coefficient.
- Animal
- Human Disease Modelled
- Intervention
- Escitalopram, Agomelatine, duloxetine, Escitalopram oxalate, Sertraline salate, fluoxetine, paroxetine, bupropion, venlafaxine, mirtazapine, ziprasidone, citalopram, Trazodone hydrochloride, ketamine, Flurperthiazide meritracine tablets, etc. Resolve depression pill, Shugan Jieyu capsule, Peripateticism pill, Jiuwei Zhen Xin Granules, Oyster soup with bupleurum and keel, Wendan tang, Liver-soothing jieyu soup, etc.
- Comparator Control
- placebo
- Main Outcome
- effective rate, safety Measures of effect odd ratios
- Outcome Measure
- Additional Outcome
- Depression Scale Measures of effect mean difference
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Humans
- Contact
- Minjie Cai [email protected]
- Organisational Affiliation
- Guangzhou University of Chinese Medicine
- Funding Source
- Yunnan Provincial Department of Science and Technology - Chinese Medicine Joint Project (2019FF002-068);Science and Technology Innovation Team of Acupuncture and Moxibustion prevention and Treatment of Mental Illness in Universities of Yunnan Province (2019)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-06-27
- Registration Date
- 2020-07-30
- Anticipated Start Date
- 2020-07-01
- Anticipated Completion Date
- 2020-12-31
- Title Cn
- 不同抗抑郁药与中成药治疗成人重度抑郁障碍急性期的疗效和可接受性比较：系统评价与网状Meta分析
- Title En
- Comparative efficacy and acceptability of different antidepressant drugs and Chinese patent medicine for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
- Bilingual Status
- complete